Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hazard Rate01:11

Hazard Rate

521
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
521
Hazard Ratio01:12

Hazard Ratio

750
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
750
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

706
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
706
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

782
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
782

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comment on "Causal interpretation of the hazard ratio in randomized clinical trials" by Fay and Li.

Clinical trials (London, England)·2024
Same author

Estimating the optimal timing of surgery by imputing potential outcomes.

Statistics in medicine·2021
Same author

Analysis of local sensitivity to nonignorability with missing outcomes and predictors.

Biometrics·2021
Same author

Statistical modeling and prediction of clinical trial recruitment.

Statistics in medicine·2018
Same author

Estimating lead-time bias in lung cancer diagnosis of patients with previous cancers.

Statistics in medicine·2018
Same author

Proximity and gravity: modeling heaped self-reports.

Statistics in medicine·2017
Same journal

A statistical evaluation of decision-making methods and the efficiency of Bayesian multi-arm multi-stage trials.

Clinical trials (London, England)·2026
Same journal

Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.

Clinical trials (London, England)·2026
Same journal

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026
Same journal

Trial informed consent forms, the Declaration of Helsinki and the SPIRIT 2025 statement.

Clinical trials (London, England)·2026
Same journal

17th Annual University of Pennsylvania Conference on statistical issues in clinical trials - Covariate adjustment in randomized clinical trials: New methods and applications (Morning panel discussion).

Clinical trials (London, England)·2026
Same journal

17th Annual University of Pennsylvania Conference on statistical issues in clinical trials - Covariate adjustment in randomized clinical trials: New methods and applications (Afternoon panel discussion).

Clinical trials (London, England)·2026
See all related articles

Related Experiment Video

Updated: Apr 25, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

9.8K

Estimating clinical trial hazard functions.

Daniel F Heitjan1,2

  • 1Department of Statistics and Data Science, Southern Methodist University, Dallas, TX, USA.

Clinical Trials (London, England)
|April 24, 2026
PubMed
Summary
This summary is machine-generated.

Estimating hazard functions in clinical trials is crucial. Novel flexible parametric models, using Bayesian model averaging, provide a robust method for accurately recovering hazard function shapes, improving survival analysis.

Keywords:
Clinical trialhazard functionproportional hazards modelsurvival analysis

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K

Related Experiment Videos

Last Updated: Apr 25, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

9.8K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K

Area of Science:

  • Biostatistics
  • Clinical Trial Analysis
  • Survival Analysis

Background:

  • Event-based clinical trial analysis often assumes underlying hazard functions.
  • Estimating these hazard functions in practice is infrequently performed.

Purpose of the Study:

  • To describe and evaluate methods for estimating hazard functions in clinical trials.
  • To compare conventional parametric modeling with novel flexible modeling approaches.

Main Methods:

  • Utilized discrete and discretized continuous survival models.
  • Employed parametric modeling, Bayesian model averaging, splines, and fractional polynomials.
  • Conducted a Monte Carlo simulation study and analyzed three historical clinical trials.

Main Results:

  • Flexible models, particularly spline modeling, effectively captured hazard function features like multimodality.
  • Spline modeling demonstrated reliability with good coverage probabilities and modest efficiency loss.
  • Discreteness of measurements had minimal impact on estimated hazard function shapes.
  • Departures from the proportional hazards assumption were observed in datasets, though not always detected by tests.

Conclusions:

  • Flexible parametric models within a Bayesian model averaging framework offer a robust method for hazard function estimation.
  • Visualizing the hazard function can significantly enhance conventional survival analyses.
  • These methods improve the understanding of event-time data in clinical research.